Published On: Sat, Oct 5th, 2013

Advanced BioScience Laboratories chosen to help develop Shigella vaccine candidate

Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced earlier this week that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.  ABL will develop a scalable production process under current Good Manufacturing Practices (cGMPs) to produce toxicology and Phase I clinical supply at its state-of-the-art facility located in Rockville, MD.

Photo/CDC/ Debora Cartagena

Photo/CDC/ Debora Cartagena

The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Dr. Wendy Picking at the Department of Microbiology and Molecular Genetics, Oklahoma State University.  The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes.

Dr. Thomas VanCott, President and CEO of ABL, stated, “We are very pleased to have been chosen by PATH to be the contract manufacturer for this important vaccine candidate.  Our expertise in the areas of cGMP manufacturing, assay development, and project management combine to provide a unique and comprehensive service for vaccine development from early-stage discovery to clinical trials.”

Shigella  is actually a family of bacteria that can cause diarrhea (shigellosis) in humans, according to the CDC. There are several different kinds of Shigella bacteria: Shigella sonnei, also known as “Group D” Shigella, accounts for over two-thirds of shigellosis in the United States. Shigella flexneri, or “group B” Shigella, accounts for almost all the rest. Other types of Shigella are rare in this country, though they continue to be important causes of disease in the developing world. One type found in the developing world,Shigella dysenteriae type 1, can cause deadly epidemics.

Most who are infected with Shigella develop diarrhea, fever, and stomach cramps starting a day or two after they are exposed to the bacteria. The diarrhea is often bloody. Shigellosis usually resolves in 5 to 7 days. Persons with shigellosis in the United States rarely require hospitalization.

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products.

Press Release

For more infectious disease news and information, visit and “like” the Infectious Disease News Facebook page

Looking for a job in health care? Check here to see what’s available

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required

About the Author

- Writer, Co-Founder and Executive Editor of The Global Dispatch. Robert has been covering news in the areas of health, world news and politics for a variety of online news sources. He is also the Editor-in-Chief of the website, Outbreak News Today and hosts the podcast, Outbreak News Interviews on iTunes, Stitcher and Spotify Robert is politically Independent and a born again Christian Follow @bactiman63

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>



The Global Dispatch Facebook page- click here

Movie News Facebook page - click here

Television News Facebook page - click here

Weird News Facebook page - click here